Ocular Therapeutix (NASDAQ: OCUL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.260 | -0.220 | 0.0400 | ||||
REV | 14.200M | 13.187M | -1.013M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ocular Therapeutix (NASDAQ: OCUL) through any online brokerage.
Other companies in Ocular Therapeutix’s space includes: GH Research (NASDAQ:GHRS), Aerie Pharmaceuticals (NASDAQ:AERI), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Ocular Therapeutix (NASDAQ: OCUL) was reported by JMP Securities on Tuesday, May 10, 2022. The analyst firm set a price target for 20.00 expecting OCUL to rise to within 12 months (a possible 434.76% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Ocular Therapeutix (NASDAQ: OCUL) is $3.74 last updated Today at June 28, 2022, 6:10 PM UTC.
There are no upcoming dividends for Ocular Therapeutix.
Ocular Therapeutix’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Ocular Therapeutix.
Ocular Therapeutix is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.